Monday, September 16, 2013

30+ Life Science Investors & Strategic Partners Convene In Denver This Week For 2013 Rocky Mountain Life Science Investor & Partnering Conference

More than thirty of the industry’s leading investors and strategic partners will attend presentations by the region’s most innovative life science companies at the 2013 Rocky Mountain Life Science Investor and Partnering Conference (RMLIPC), September 18-19 at the The Ritz-Carlton, Denver.

The announcement is made by April Giles, President & CEO of the Colorado BioScience Association (CBSA) who says, “Leading biotech, medical device, diagnostic and pharmaceutical investors from across the country will be coming to Denver to connect and invest in the regions emerging life science companies. Each company will make a 10-minute presentation to an audience of their peers, investors and partners, followed by a 5-minute period of questions—this type of high-pressure pitching is typical in vying for highly coveted VC funding.”

“The RMLIPC really showcases the best companies from the region and provides investors an opportunity to evaluate these fresh investment opportunities and meet one-on-one with their founders and executive team,” said Giles. “It’s important to note, the Rocky Mountain region is a key player in the life science industry. There has been over $1 billion in investment in the region over the past five years.”

The following investors and strategic partners will be attending RMLIPC 2013: 

Amgen Ventures, Thousand Oaks, CA -
Aphelion Capital, Mill Valley, CA -  
Bay City Capital, San Francisco, CA -
BioGenerator, St. Louis, MO -  
Boulder Ventures, Boulder, CO -  
Charter Life Sciences, Santa Clara, CA -  
Covidien, Mansfield, MA -
Epic Ventures, Albuquerque, NM -
GE Healthcare Financial Services, Chicago, IL -
Goodworks Ventures, MT -
High Country Venture, Boulder, CO -  
Johnson & Johnson Development Corporation, New Brunswick, NJ -  
KMG Capital Partners, Denver CO
Level 5 Partners, Fort Collins, CO -  
Lightstone Ventures, Boulder, CO -  
Mercury Fund, Houston, TX -  
Mile High Fund, Denver, CO -  
Morgenthaler Ventures, Menlo Park, CA  -  
New Enterprise Associates, Menlo Park, CA -  
Novartis Venture Funds, Cambridge, MA -  
Red Script Ventures, New Brunswick, NJ -
Remeditex, Dallas, TX -  
Salt Lake Life Science Angels, Salt Lake City, UT - 
Sanderling Ventures, San Mateo, CA -  
Signal Peak Ventures, Salt Lake City, UT -     
Silicon Valley Bank, Broomfield, CO -
Split Rock Partners, Menlo Park, CA -  
SR One, Corporate VC Arm of GlaxoSmithKline, San Francisco, CA -
Volcano Capital, New York, NY -  
Wayne Brown Institute, Salt Lake City, UT -  

Wexford Capital LP, Greenwich, CT -  

About the Rocky Mountain Life Science Investor & Partnering Conference 

The 2013 Rocky Mountain Life Science Investor & Partnering Conference – spearheaded by the Colorado BioScience Association in collaboration with associations in Arizona, Montana, New Mexico and Utah — will open with a reception at the Colorado Governor’s Mansion September 18th and follow with a full day of company pitch presentations September 19th. The keynote breakfast will include Kyle Lefkoff, founder and General Partner of Boulder Ventures, leading a conversation with the CEOs of Colorado's two premier publicly-traded pharmaceutical companies-Patrick Mahaffy, Founder and CEO of Clovis Oncology and Ron Squarer, CEO of Array BioPharma. The keynote lunch titled “New Approaches to Healthcare Innovation” will be a presentation from Jeff Calcagno, M.D., Venture Investments with Johnson & Johnson Development Corporation. For more information and registration details, visit

On Twitter, please use the hashtag #RockyMtnBioInvest for your tweets.

No comments:

Post a Comment